一个多功能益生菌联合交付平台用于治疗Clostridium difficile感染
Hao Yang1, Yanling Kuang1, Lamei Wang2
1College of Animal Science and Technology, Northwest A&F University, Yangling, Shaanxi Province, China.
概括
一个新的水凝平台提供益生菌和纳米颗粒来对抗Clostridioides difficile感染 (CDI). 这种方法增强了肠道修复,减少了炎症,并恢复了微生物平衡,在模型中表现优于万科米辛.
科学领域:
- 微生物学 微生物学
- 生物材料科学 生物材料科学
- 胃肠病学 胃肠病学
背景情况:
- 艰难杆菌感染 (CDI) 破坏了肠道微生物平衡,抗生素往往无法恢复平衡.
- 目前的益生菌疗法在生存能力,向性分娩和抑制C. difficile毒性方面面临挑战.
- 需要一个新的战略,通过解决这些局限性来有效管理CDI.
研究的目的:
- 开发一个协同协同的联合交付平台,以加强Clostridioides difficile感染 (CDI) 管理.
- 评估一种新型水凝平台 (BA@HF-PDAT) 在改善CDI诱导的大肠炎方面的疗效.
- 调查开发的平台治疗效果背后的机制.
主要方法:
- 基于多糖的水凝平台 (HF) 的开发,用于同时输送Bifidobacterium adolescentis (BA) 和多多巴胺-甲基醇纳米颗粒 (PDA-TH NPs).
- 在实验室和体内研究中,使用CDI的小鼠模型来评估治疗疗效,肠道修复和抗炎/抗氧化活性.
- 对肠道微生物组成,代谢功能和Wnt/β-catenin信号通路调节的分析.
主要成果:
- BA@HF-PDAT水凝平台显著提高了益生菌的活力,结肠向释放和植入.
- 该平台表现出强大的抗炎和抗氧化作用,通过Wnt/β-catenin信号传递促进肠道修复和减轻亡.
- 观察到肠道微生物组成和代谢功能的恢复,有效地改善了CDI诱导的大肠炎.
- 在小鼠模型中,BA@HF-PDAT显示出与科米辛治疗相比更高的治疗效果.
结论:
- 集成的联合交付平台BA@HF-PDAT提供了一个有前途的治疗策略,用于Clostridioides difficile感染 (CDI).
- 这种方法协同结合了益生菌的益处与针对性抑制C. difficile毒性因子.
- 该平台促进肠道修复,调节炎症,恢复肠道微生物群,代表了对CDI管理的转化治疗选择.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
618
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
618
01:29Drugs for Treatment of Ulcerative Colitis in IBD
449
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
449
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
193
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
193
01:21Drugs for Treatment of Constipation-Predominant IBS
698
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
698
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
412
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
412
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480